1103 related articles for article (PubMed ID: 28061006)
1. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
2. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
3. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
[TBL] [Abstract][Full Text] [Related]
4. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
5. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.
Hoang LN; Kinloch MA; Leo JM; Grondin K; Lee CH; Ewanowich C; Köbel M; Cheng A; Talhouk A; McConechy M; Huntsman DG; McAlpine JN; Soslow RA; Gilks CB
Am J Surg Pathol; 2017 Feb; 41(2):245-252. PubMed ID: 28079598
[TBL] [Abstract][Full Text] [Related]
6. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.
Talhouk A; Hoang LN; McConechy MK; Nakonechny Q; Leo J; Cheng A; Leung S; Yang W; Lum A; Köbel M; Lee CH; Soslow RA; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2016 Oct; 143(1):46-53. PubMed ID: 27421752
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
10. A clinically applicable molecular-based classification for endometrial cancers.
Talhouk A; McConechy MK; Leung S; Li-Chang HH; Kwon JS; Melnyk N; Yang W; Senz J; Boyd N; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Br J Cancer; 2015 Jul; 113(2):299-310. PubMed ID: 26172027
[TBL] [Abstract][Full Text] [Related]
11. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
[TBL] [Abstract][Full Text] [Related]
12. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
13. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
14. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
Cosgrove CM; Tritchler DL; Cohn DE; Mutch DG; Rush CM; Lankes HA; Creasman WT; Miller DS; Ramirez NC; Geller MA; Powell MA; Backes FJ; Landrum LM; Timmers C; Suarez AA; Zaino RJ; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
Gynecol Oncol; 2018 Jan; 148(1):174-180. PubMed ID: 29132872
[TBL] [Abstract][Full Text] [Related]
15. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
[TBL] [Abstract][Full Text] [Related]
16. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
17. [Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma].
Du NN; Liu Y; Ren CX; Wang YX; Du J; Yang J; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):596-603. PubMed ID: 31422589
[No Abstract] [Full Text] [Related]
18. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
19. Histopathological characterization of ProMisE molecular groups of endometrial cancer.
Raffone A; Travaglino A; Mascolo M; Carotenuto C; Guida M; Mollo A; Insabato L; Zullo F
Gynecol Oncol; 2020 Apr; 157(1):252-259. PubMed ID: 31932106
[TBL] [Abstract][Full Text] [Related]
20. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting.
Casey L; Singh N
Int J Gynecol Pathol; 2021 Jan; 40(1):5-16. PubMed ID: 33290350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
